BioStock: Cereno Scientific’s CBO about his new role

Cereno Scientific’s clinical and preclinical programmes in cardiovascular disease are progressing strongly. In light of that, the company has been taking steps to ensure it has the right competence and expertise to support driving optimal development forward of its portfolio of drug candidates for patients with rare and common cardiovascular disease where there is a significant unmet need. Several new management appointments were made at the company recently, including recruiting Etienne Adriansen as Chief Business Officer. BioStock got in touch with Adriansen to ask him a few questions about his new role.

Read the full interview with Etienne Adriansen at biostock.se:

https://www.biostock.se/en/2023/03/cereno-scientifics-cbo-about-his-new-role/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/